These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 18022002

  • 21. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
    Chieffo A, Foglieni C, Nodari RL, Briguori C, Sangiorgi G, Latib A, Montorfano M, Airoldi F, Michev I, Carlino M, Colombo A, Maseri A.
    Am J Cardiol; 2009 Dec 15; 104(12):1660-7. PubMed ID: 19962471
    [Abstract] [Full Text] [Related]

  • 22. Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels.
    Quizhpe AR, Feres F, de Ribamar Costa J, Abizaid A, Maldonado G, Costa R, Abizaid A, Cano M, Moreira AC, Staico R, Mattos LA, Tanajura LF, Chaves A, Centemero M, Sousa AM, Sousa JE.
    Am Heart J; 2007 Aug 15; 154(2):373-8. PubMed ID: 17643591
    [Abstract] [Full Text] [Related]

  • 23. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry.
    Yan BP, Ajani AE, New G, Duffy SJ, Farouque O, Shaw J, Sebastian M, Lew R, Brennan A, Andrianopoulos N, Reid C, Clark DJ, Melbourne Interventional Group Investigators.
    Int J Cardiol; 2008 Nov 28; 130(3):374-9. PubMed ID: 18706719
    [Abstract] [Full Text] [Related]

  • 24. Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes.
    Tamburino C, Di Salvo ME, Capodanno D, Palmerini T, Sheiban I, Margheri M, Vecchi G, Sangiorgi G, Piovaccari G, Bartorelli A, Briguori C, Ardissino D, Di Pede F, Ramondo A, Inglese L, Petronio AS, Bolognese L, Benassi A, Palmieri C, Filippone V, De Servi S.
    Am J Cardiol; 2009 Jan 15; 103(2):187-93. PubMed ID: 19121434
    [Abstract] [Full Text] [Related]

  • 25. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L.
    Circulation; 2008 Nov 25; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [Abstract] [Full Text] [Related]

  • 26. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S, Herdeg C.
    Herz; 2008 Apr 25; 33(3):196-205. PubMed ID: 18568314
    [Abstract] [Full Text] [Related]

  • 27. Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry.
    Tamburino C, Di Salvo ME, Capodanno D, Marzocchi A, Sheiban I, Margheri M, Maresta A, Barlocco F, Sangiorgi G, Piovaccari G, Bartorelli A, Briguori C, Ardissino D, Di Pede F, Ramondo A, Inglese L, Petronio AS, Bolognese L, Benassi A, Palmieri C, Patti A, De Servi S.
    Eur Heart J; 2009 May 25; 30(10):1171-9. PubMed ID: 19276194
    [Abstract] [Full Text] [Related]

  • 28. Coronary collateral function long after drug-eluting stent implantation.
    Meier P, Zbinden R, Togni M, Wenaweser P, Windecker S, Meier B, Seiler C.
    J Am Coll Cardiol; 2007 Jan 02; 49(1):15-20. PubMed ID: 17207716
    [Abstract] [Full Text] [Related]

  • 29. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M, Pasquet A, Preumont V, Kefer J, Hermans MP, Vanoverschelde JL, Buysschaert M.
    Diabetes Metab; 2008 Feb 02; 34(1):62-7. PubMed ID: 18069029
    [Abstract] [Full Text] [Related]

  • 30. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A, Jensen LO, Maeng M, Tilsted HH, Thayssen P, Bøttcher M, Lassen JF, Krusell LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Sørensen HT, Thuesen L.
    J Am Coll Cardiol; 2009 Feb 24; 53(8):658-64. PubMed ID: 19232897
    [Abstract] [Full Text] [Related]

  • 31. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET.
    Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, Leibundgut G, Bader F, Kaiser C, BASKET.
    Eur Heart J; 2009 Jan 24; 30(1):16-24. PubMed ID: 19033260
    [Abstract] [Full Text] [Related]

  • 32. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P, Kaplan S, Dimopoulos K, Ferrante G, Di Mario C.
    Cardiology; 2008 Jan 24; 111(4):270-6. PubMed ID: 18451644
    [Abstract] [Full Text] [Related]

  • 33. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials.
    Sanchez-Recalde A, Moreno R, Barreales L, Rivero F, Galeote G, Jimenez-Valero S, Calvo L, López de Sá E, López-Sendón JL.
    J Invasive Cardiol; 2008 Aug 24; 20(8):417-22. PubMed ID: 18688067
    [Abstract] [Full Text] [Related]

  • 34. Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings.
    Harjai KJ, Orshaw P, Boura J, Sporn D.
    Am J Cardiol; 2009 Jun 01; 103(11):1537-45. PubMed ID: 19463512
    [Abstract] [Full Text] [Related]

  • 35. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
    Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, Cuomo LJ, Wong SC.
    J Interv Cardiol; 2007 Dec 01; 20(6):458-65. PubMed ID: 18042050
    [Abstract] [Full Text] [Related]

  • 36. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
    Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, Handke M, Osswald S, Buser PT, Pfisterer ME, BASKET Investigators.
    Cardiology; 2009 Dec 01; 112(1):49-55. PubMed ID: 18580059
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C, Barbagallo R, Capodanno D, di Matteo S, Colombo GL, Recchia M, Ciriminna S, Sicilian DES Registry Investigators.
    J Cardiovasc Med (Hagerstown); 2009 Apr 01; 10(4):322-9. PubMed ID: 19430343
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions.
    Li JJ, Qin XW, Yang XC, Li ZC, Zeng HS, Xu B, Gao Z, Wu YJ, Zhang X, Zhang CY.
    Clin Chim Acta; 2008 Oct 01; 396(1-2):38-42. PubMed ID: 18634770
    [Abstract] [Full Text] [Related]

  • 40. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study.
    Toutouzas K, Patsa C, Tsiamis E, Tsioufis C, Spanos A, Stefanadi E, Tentolouris C, Stefanadis C.
    J Interv Cardiol; 2008 Oct 01; 21(5):388-94. PubMed ID: 18705639
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.